Kota Biotherapeutics

Kota Biotherapeutics was a private biotechnology startup focused on cell therapies for the immune system. Available public information indicates the company was incubated at Intellectual Ventures and worked on engineered B-cell-based therapeutic platforms, including modified cytotoxic B lymphocytes capable of expressing reassigned biological agents and recombinant B-cell receptors. Its patent estate suggests an approach combining antibody production with engineered immune effector function, with potential applications in oncology and broader immune-mediated disease. The company appears to have remained preclinical, with no disclosed clinical-stage pipeline or marketed products. Corporate registry records in Washington and California indicate the entity is no longer active.